Expert Interview
Digging into the results for Astrazeneca's CALYPSO Phase III trial of eneboparatide (AZP-3601) in chronic hypoparathyroidism
Ticker(s): AZNInstitution: Children's Hospital of Philadelphia
- Chief Emeritus of Endocrinology and Diabetes and Director of the Center for Bone Health at The Children’s Hospital of Philadelphia & Professor Emeritus of Pediatrics and Medicine at the University of Pennsylvania Perelman School of Medicine.
- Research interests focus on the genetic basis of endocrine signaling defects; his approach is to apply molecular and genetic tools to analyze the basis of altered hormone action, particularly in G protein-coupled signal transduction systems that affect growth and development.
- Identified the molecular basis of several inherited disorders of mineral metabolism, including familial hypoparathyroidism, pseudohypoparathyroidism, and the McCune Albright syndrome.
How do you interpret the clinical impact of the CALYPSO trial results for eneboparatide in the context of current treatment options for chronic hypoparathyroidism?
Added By: dami_adminWhat potential advantages or concerns do you foresee with the use of eneboparatide as a PTH receptor agonist in routine clinical practice?
Added By: dami_adminHow might the use of eneboparatide change the standard of care or treatment algorithm for chronic hypoparathyroidism if approved?
Added By: dami_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
